Replies to post #4389 on Kitov Pharmaceuticals Hldgs L Sponsored ADR (KTOV)

[tykundegex]

Agreed, Pfizer would make a logical buyer, and could likely be more successful with KIT-302 than another buyer, precisely due to the Celebrex brand and sales channels they have. But they'll never see the same peak sales. I would hope for $1.5B from KIT-302 (last year Celebrex sales were ~ $830MM and still dropping). So buying KIT-302 would cannibalize their Celebrex sales, but could double the revenue from it. A net benefit of about $750m annually.

At 4x that benefit, KIT-302 is worth $3B.

All just for fun.. of course I'd be happy with $20/share ;-)

[coyote00]

So what would selling the drug and not the company do to the stock price and value? This seems feasible as the reason for the last offering to raise capital back in June was to raise funds to start trials on their next drug if I am not mistaken. This could be the route they are planning.